RxDoctor Payments Data

Sheri Pham, MD

Nephrology · Glendora, CANPI 1639261951

Payments from drug & device makers

$9,684in general payments, 2019–2025

Across 287 payments — averaging $33.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Amgen$845
  • Akebia Therapeutics Inc$748
  • Vifor Pharma, Inc.$655
  • Novo Nordisk$426
  • Bayer$426
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$9,62099%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,684 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$683,235
Medicare patients
574
Services billed
5,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate265$219,118
VeltassaPatiromer Calcium Sorbitex91$98,181
ProcritEpoetin Alfa46$87,946
FarxigaDapagliflozin Propanediol114$71,886
KerendiaFinerenone31$19,597
AuryxiaFerric Citrate35$14,988
TradjentaLinagliptin17$9,761
DapagliflozinDapagliflozin Propanediol15$7,930
Sevelamer Carbonate47$7,352
Calcium Acetate81$5,586
SpsSodium Polystyrene Sulfon/Sorb12$2,478
Hydralazine Hcl190$1,846
Valganciclovir Hcl15$1,200
Midodrine Hcl19$866
Amlodipine Besylate229$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$3,327$291,005379 claims
BayerKerendia$426$19,59731 claims
Akebia Therapeutics IncAuryxia$748$14,98835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.

Other nephrology in Glendora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →